BRPI0924033A2 - compostos heterocíclicos como inibidores de metap-2 - Google Patents

compostos heterocíclicos como inibidores de metap-2

Info

Publication number
BRPI0924033A2
BRPI0924033A2 BRPI0924033A BRPI0924033A BRPI0924033A2 BR PI0924033 A2 BRPI0924033 A2 BR PI0924033A2 BR PI0924033 A BRPI0924033 A BR PI0924033A BR PI0924033 A BRPI0924033 A BR PI0924033A BR PI0924033 A2 BRPI0924033 A2 BR PI0924033A2
Authority
BR
Brazil
Prior art keywords
metap
inhibitors
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
BRPI0924033A
Other languages
English (en)
Inventor
Frank Zenke
Kai Schiemann
Mireille Krier
Timo Heinrich
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0924033A2 publication Critical patent/BRPI0924033A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0924033A 2009-01-20 2009-12-22 compostos heterocíclicos como inibidores de metap-2 BRPI0924033A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009005193A DE102009005193A1 (de) 2009-01-20 2009-01-20 Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
PCT/EP2009/009218 WO2010083870A1 (de) 2009-01-20 2009-12-22 Neue heteroclyclische verbindungen als metap-2 inhibitoren

Publications (1)

Publication Number Publication Date
BRPI0924033A2 true BRPI0924033A2 (pt) 2016-01-26

Family

ID=42210278

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924033A BRPI0924033A2 (pt) 2009-01-20 2009-12-22 compostos heterocíclicos como inibidores de metap-2

Country Status (16)

Country Link
US (1) US8546406B2 (pt)
EP (1) EP2379558B1 (pt)
JP (1) JP5619025B2 (pt)
KR (1) KR20110112434A (pt)
CN (1) CN102292339B (pt)
AR (1) AR075035A1 (pt)
AU (1) AU2009337953B2 (pt)
BR (1) BRPI0924033A2 (pt)
CA (1) CA2749970C (pt)
DE (1) DE102009005193A1 (pt)
EA (1) EA201101090A1 (pt)
ES (1) ES2575687T3 (pt)
IL (1) IL213935A (pt)
MX (1) MX2011007641A (pt)
SG (1) SG174118A1 (pt)
WO (1) WO2010083870A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
AU2020211684A1 (en) * 2019-01-22 2021-09-09 Merck Patent Gmbh Heterocyclic derivatives
WO2023196540A1 (en) * 2022-04-06 2023-10-12 Vanderbilt University Articles and methods for inhibiting methionine aminopeptidase activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
FR2448542A1 (fr) * 1979-02-06 1980-09-05 Landerlan Sa Lab Derives de triazolapyrimidine utiles comme medicaments
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
ES2203642T3 (es) * 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
UY26664A1 (es) 2000-04-14 2001-11-30 Abbott Lab Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis.
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
WO2002081415A2 (en) 2001-04-03 2002-10-17 Smithkline Beecham Corporation Method for inhibiting metap2
JP4306206B2 (ja) * 2001-09-04 2009-07-29 住友化学株式会社 イミダゾ［１，２−ａ］ピリミジン、その用途およびその製造中間体
WO2004108136A1 (en) * 2003-06-04 2004-12-16 Vernalis (Cambridge) Limited Triazolo `1 , 5-a!pyrimidines and their use in medicine
CN1933844A (zh) * 2003-12-22 2007-03-21 吉里德科学公司 激酶抑制剂膦酸酯缀合物
US20050153989A1 (en) * 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
MY139689A (en) * 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AU2006227790B2 (en) * 2005-03-15 2009-09-10 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102005037733A1 (de) 2005-08-10 2007-02-15 Merck Patent Gmbh Adeninderivate
WO2008012635A2 (en) * 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren

Also Published As

Publication number Publication date
CN102292339B (zh) 2015-01-28
CA2749970A1 (en) 2010-07-29
EP2379558A1 (de) 2011-10-26
WO2010083870A1 (de) 2010-07-29
US8546406B2 (en) 2013-10-01
AU2009337953B2 (en) 2016-02-11
DE102009005193A1 (de) 2010-07-22
US20110281859A1 (en) 2011-11-17
JP2012515731A (ja) 2012-07-12
AU2009337953A1 (en) 2011-09-01
SG174118A1 (en) 2011-10-28
EP2379558B1 (de) 2016-03-23
IL213935A (en) 2017-06-29
CA2749970C (en) 2017-11-28
JP5619025B2 (ja) 2014-11-05
IL213935A0 (en) 2011-07-31
KR20110112434A (ko) 2011-10-12
EA201101090A1 (ru) 2012-03-30
AR075035A1 (es) 2011-03-02
MX2011007641A (es) 2011-09-06
CN102292339A (zh) 2011-12-21
ES2575687T3 (es) 2016-06-30

Similar Documents

Publication Publication Date Title
BR112012000792A2 (pt) compostos heterocíclicos como inibidores de autotaxina
BRPI1009800A2 (pt) compostos heterocíclicos como inibidores de autotaxina
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI1015038A2 (pt) derivados espiro azacíclicos como inibidores de hsl
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BR112013008886A2 (pt) pirrolidinonas como inibidores de metap-2
CO6831983A2 (es) Compuestos heterocíclicos como inhibidores de cinasas
BR112013015449A2 (pt) compostos de bi-heteroarila como inibidores de vps23
BRPI1015238A2 (pt) diamidas de azetidilina como inibidores de monoaciglicerol lipase
BRPI0916375A2 (pt) compostos orgânicos como inibidores de smo
BR112012029405A2 (pt) compostos macrocíclicos como inibidores de trk quinase
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BRPI0925050A2 (pt) Compostos heterocíclicos como inibidores de mek
BR112012005616A2 (pt) compostos antivirais heterocíclicos
BRPI1005525A2 (pt) compostos de azaazuleno
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI1014077A2 (pt) Derivados de tiazolilperidina como fungicidas
BRPI0912475A8 (pt) compostos como inibidores de quinase
BRPI1010852A2 (pt) compostos antivirais heterocíclicos
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
BRPI1016266A2 (pt) compostos antivirais heterocíclicos
SMT201600031B (it) Composti eterociclici di fenossimetile
BR112012005382A2 (pt) inibidores de jak
BRPI0920053A2 (pt) pirazolilaminopiridinas como inibidores da fak

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]